ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,475.32
-0.21%
Dow Jones
39,100.50
0.68%
US Dollar vs MXN
18.34952
-0.46%
Brent Oil
85.095
0.47%
Bitcoin
64,984.46
0.03%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Quince Therapeutics Inc (QNCX)

  7. Quince Therapeutics Inc (QNCX) Noticias

QNCX Quince Therapeutics Inc

0.65
-0.03 (-4.41%)
Última actualización: 14:28:57
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Quince Therapeutics Inc QNCX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.03 -4.41% 0.65 14:28:57
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.69 0.65 0.6917 0.68
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
07/6/202420:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202420:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202419:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202416:17EDGAR2Form 8-K - Current report
05/6/202413:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202406:00BWQuince Therapeutics Receives U.S. FDA Fast Track Designation..
13/5/202406:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202406:00BWQuince Therapeutics Provides Business Update and Reports..
06/5/202415:05BWQuince Therapeutics to Present at The Citizens JMP Life..
01/4/202406:00BWQuince Therapeutics Provides Business Update and Reports..
22/2/202406:00BWQuince Therapeutics Launches Scientific Advisory Board
15/2/202415:00EDGAR2Form 8-K - Current report
15/2/202406:00BWQuince Therapeutics Appoints Former Reata Pharmaceuticals..
07/2/202415:05BWQuince Therapeutics to Present at Oppenheimer 34th Annual..
02/2/202416:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:01EDGAR2Form 8-K/A - Current report: [Amend]
04/1/202415:05BWQuince Therapeutics to Participate at Investor Events in..
03/1/202415:02EDGAR2Form 8-K - Current report
22/12/202315:08EDGAR2Form 8-K - Current report
14/12/202317:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202315:06EDGAR2Form 8-K - Current report
07/12/202317:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202312:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/10/202316:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/10/202318:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/10/202318:34EDGAR2Form 3 - Initial statement of beneficial ownership of..
23/10/202315:05EDGAR2Form 8-K - Current report
23/10/202306:00BWQuince Therapeutics Completes Acquisition of EryDel S.p.A.
28/9/202315:53DJNQuince Therapeutics to Advance Study of EryDex as FDA Lifts..
28/9/202315:05BWU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s..
06/9/202306:18EDGAR2Form 8-K - Current report
06/9/202306:00BWQuince Therapeutics Appoints Dr. Charles S. Ryan as..
31/8/202317:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202317:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202316:05EDGAR2Form 8-K - Current report
10/8/202315:05BWQuince Therapeutics to Present at Sidoti Virtual Investor..
09/8/202317:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202317:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202315:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
24/7/202316:56BWQuince Therapeutics rileva EryDel SpA e il suo asset di fase..
24/7/202306:16EDGAR2Form 8-K - Current report
24/7/202306:00BWQuince Therapeutics to Acquire EryDel SpA and its Phase 3..

Su Consulta Reciente

NASDAQ
QNCX
Quince Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados